非酒精性脂肪性肝病的危险因素

脂肪[主要是甘油三酯（TG）]在肝细胞中的过度沉积，达到5％的肝脏质量或30％的肝细胞脂肪沉积称为脂肪肝。目前脂肪肝分为酒精性脂肪性肝病与非酒精性脂肪性肝病（NAFLD）两大类。NAFLD中伴有肝脏炎症、坏死、纤维化、Mallory玻璃样交、气球样变性等组织学改变的病例称为非酒精性脂肪性肝炎（NASH）。     

对非酒精性脂肪性肝病患者综合干预的探讨

非酒精性脂肪性肝病（nonalcoholic fatty liver disease,NAFLD）是临床上常见的慢性肝病之一,最早无特异性临床表现,多在体检时发现。NAFLD的发病机理尚不完全清楚,国内外研究显示,肥胖、Ⅱ型糖尿病和高血脂症是NAFLD的重要危险因素[1],无症状性肝酶升高也是NAFLD的重要表现[2]。     

内质网应激在非酒精性脂肪性肝病中的作用及植物化学物的保护效应研究进展

目的 对内质网应激（endoplasmic reticulum stress, ERs）与非酒精性脂肪性肝病（nonalcoholic fatty liver disease, NAFLD）的关系以及植物化学物的保护作用进行综述。方法 以“非酒精性脂肪性肝病/ nonalcoholic fatty liver disease”、“内质网应激/ endoplasmic reticulum stress”和“非折叠蛋白反应/ unfolded protein response”的中英文为检索词,检索2010 - 2020年收录于中国知网、万方数据库、维普资讯、Pubmed、Science Direct和Springer数据库的中英文文献。结果 ERs通过引起肝脏脂肪堆积、炎症和细胞凋亡导致NAFLD。多酚类,萜类和皂甙类等多种植物化学物通过调节ERs发挥NAFLD保护效应。结论 ERs在NAFLD发生发展中具有重要作用,开发利用具有调节ERs作用的植物化学物将为NAFLD的防治提供新的策略。     

甘草酸二铵肠溶胶囊治疗脂肪性肝病疗效观察

脂肪肝是由多种原因引起的肝细胞内脂肪（甘油三酯）堆积过多而引发的病变,是常见的慢性肝病之一。脂肪肝包括非酒精性脂肪肝（NAFLD）和酒精性脂肪肝（ALD）。有研究显示,成人群体ALD患病率为4～6,经济发达地区成人NAFLD患病率在15％左右。因此,探索治疗药物的临床效果具有重要意义,我院采用甘草酸二铵肠溶胶囊治疗脂肪肝．取得满意疗效,现报告如下。     

非酒精性脂肪肝的多囊卵巢综合征患者的临床资料分析

目的:探讨伴非酒精性脂肪肝的多囊卵巢综合征患者的临床症状及相关指标。方法:收集50例非酒精性脂肪肝的多囊卵巢综合征患者的临床资料(观察组);同时收集无非酒精性脂肪肝的50例PCOS患者的临床资料(对照组)。比较两组患者的体征、生殖激素、血糖血脂代谢等相关指标。结果:观察组患者的平均BMI、WHR、FINS、HOMA-IR、TC、TG、T高于对照组,HDL-C低于对照组(P<0.05);WHR、TG、HOMA-IR可能是导致PCOS患者并发NAFLD的独立危险因素(P<0.05)。结论:合并NAFLD的PCOS患者多伴有肥胖、血糖血脂代谢异常及T水平偏高,该类PCOS患者需预防非酒精性脂肪肝的发生。     

缬沙坦联合多烯磷脂酰胆碱治疗非酒精性脂肪肝的临床效果评价

非酒精性脂肪肝（NAFLD）是由于各种肝内外因素所致的肝脏脂肪代谢功能障碍。最终引起肝细胞内脂类物质蓄积过多和变性的病理综合征。NAFLD具有明显的代谢综合征的特征,与肥胖、糖尿病、高血压和血脂异常密切伴随。此病的发病机制是在复杂的遗传背景和环境因素作用下。单纯性脂肪肝和脂肪性肝炎向肝硬化的进展过程中导致脂肪代谢、糖代谢和蛋白质代谢等的异常．具体机制目前尚未清楚,对NAFLD尚缺乏十分有效且安全的药物治疗。     

非酒精性脂肪性肝病的危险因素

脂肪[主要是甘油三酯(TG)]在肝细胞中的过度沉积,达到5%的肝脏质量或30%的肝细胞脂肪沉积称为脂肪肝。目前脂肪肝分为酒精性脂肪性肝病与非酒精性脂肪性肝病(NAFLD)两大类。NAFLD中伴有肝脏炎症、坏死、纤维化、Mallory玻璃样变、气球样变性等组织学改变的病例称为非酒精性脂肪性肝炎(NASH)。能导致NAFLD的危险因素很多,包括药物、手术等。常见的药物有心舒宁、硫氮卓艹酮、硝苯地平、糖皮质激素等。但肥胖、糖尿病、高TG血症和高血压是脂肪肝最主要的危险因素,这些因素之间又相互影响、相互促进和密切相关。上述这些因素又是代谢…     

基于代谢组学探索多囊卵巢综合征合并非酒精性脂肪性肝病的病因学研究

目的探讨多囊卵巢综合征(PCOS)合并非酒精性脂肪性肝病(NAFLD)患者与单纯PCOS患者血清代谢物的差异,为PCOS合并NAFLD代谢组学研究提供依据。方法分别纳入PCOS合并NAFLD 24例及单纯性PCOS患者9例。采用超高液相色谱-质谱连用技术筛选两组研究对象的血清代谢组学差异物。结果两组血清代谢谱得到明显分离,筛选并鉴定了18种代谢差异物,包括游离脂肪酸(FFA) 5种、鞘磷脂(SM) 3种、单酰基甘油1种、磷脂酰胆碱(PC) 4种、硫化固醇3种、胆汁酸1种、苯甲酸类1种。与非NAFLD组相比,合并NAFLD的PCOS患者SM及1-花生四烯酸甘油水平升高,而FFA、PC、硫化固醇、甘氨胆酸(GCA)及马尿酸水平降低。结论与单纯性PCOS患者相比,PCOS+NAFLD患者存在更为严重的脂代谢异常,这可能是PCOS患者伴发NAFLD的重要原因。同时,受脂代谢影响,PCOS+NAFLD患者甾体类激素代谢亦出现异常。     

MicroRNA在非酒精性脂肪性肝病发病过程中作用的研究进展

微小RNA（microRNA, miRNA）是一种小的非编码RNA,参与机体的生理和病理反应。非酒精性脂肪性肝病（non-alcoholic fatty liver disease, NAFLD）是以弥漫性肝细胞大泡性脂肪变性为主要特征的临床病理综合征。近年来,有报道称miRNA在肝脏炎症、纤维化和硬化中发挥了一定的作用,尤其是在NAFLD发生发展过程中,miRNA表达特点、致病机制、临床诊治中的意义等方面引起了较大关注,故本文对此进行综述。     

2型糖尿病合并非酒精性脂肪肝的临床相关因素分析

目的：研究2型糖尿病合并非酒精性脂肪肝（NAFLD）患者的代谢特征,探讨其相关危险因素。方法：根据肝脏B超结果,将120例2型糖尿病患者分为NAFLD组和非NAFLD组,比较两组间的腰围、血脂、血糖、糖化血红蛋白（HbA1C）、C肽,计算并比较两组间的体重指数（BMI）、改良的胰岛素C肽指数（HOMA—C肤）。[结果]NAFLD组腰围、BMI、TG、LDL-C、HOMA-C肽均明显增高（P〈0．05）。结论：胰岛素抵抗、肥胖、高TG血症增加了2型糖尿病合并NAFLD的患病风险。     

Update on non-alcoholic fatty liver disease in children

Non-alcoholic fatty liver disease (NAFLD) is probably the most common cause of liver disease in the pediatric community. It is closely associated with obesity and insulin resistance. NAFLD may lead to non-alcoholic steatohepatitis (NASH). Although NASH is a prerequisite for the definition of NAFLD in adults and children, distinct differences are often apparent in the extent or location of fat, inflammation and fibrosis. Confirmation of the diagnosis of NAFLD can usually be achieved by imaging studies; however, staging the disease requires a liver biopsy. Current treatment relies on weight loss and exercise, although various insulin-sensitizing agents, antioxidants and medications appear promising. The aim of this review is to summarize what is known about pediatric NAFLD in terms of prevalence, pathogenesis, diagnosis, histology and treatment.     

Non-Alcoholic Fatty Liver Disease in Children: Focus on Nutritional Interventions

With increasing prevalence of childhood obesity, non-alcoholic fatty liver disease (NAFLD) has emerged as the most common cause of liver disease among children and adolescents in industrialized countries. It is generally recognized that both genetic and environmental risk factors contribute to the pathogenesis of NAFLD. Recently, there has been a growing body of evidence to implicate altered gut microbiota in the development of NAFLD through the gut-liver axis. The first line of prevention and treatment of NAFLD in children should be intensive lifestyle interventions such as changes in diet and physical activity. Recent advances have been focused on limitation of dietary fructose and supplementation of antioxidants, omega-3 fatty acids, and prebiotics/probiotics. Convincing evidences from both animal models and human studies have shown that reduction of dietary fructose and supplement of vitamin E, omega-3 fatty acids, and prebiotics/probiotics improve NAFLD.     

Non-alcoholic fatty liver disease in children now: lifestyle changes and pharmacologic treatments

Over the past decade, non-alcoholic fatty liver disease (NAFLD) has become one of most common chronic liver diseases in children. A greater understanding about the risk factors and molecular pathogenesis of NAFLD suggests that lifestyle interventions aiming to decrease obesity/body mass index and metabolic derangement are the first line of treatments adopted in children affected by this disease. However, because these therapeutic options are often at the beginning misjudged by the patients and their parents, the use of pharmacologic agents may help to protect the liver and other organs from further irreversible tissue damage. Pharmacologic therapies against one or more specific factors and/or molecules involved in the development of NAFLD (i.e., insulin resistance, free fatty acid lipid toxicity, and oxidative stress) also might slow the progression of this increasingly prevalent pediatric disorder. On this basis, insulin sensitizers, antioxidants, cytoprotective agents, and dietary supplementations have been evaluated in pediatric clinical trials. In this review, we discuss the efficacy of the dietary approaches, possibly coupled with regular exercise, on decreasing the metabolic and histologic damage in pediatric NAFLD. We also emphasize several advantages of the pharmacologic treatments adopted or adoptable in combination with lifestyle interventions in children with NAFLD.     

机关干部非酒精性脂肪肝病与代谢综合征的关系分析

目的探讨非酒精性脂肪肝病(NAFLD)与代谢综合征的关系。方法636例机关干部体检者经超声诊断患脂肪肝,其中474例诊断为NAFL,定为NAFL组。以超声检查无脂肪肝的104例受检者作为对照,两组间年龄和性别构成匹配。结果①NAFLD组收缩压、空腹血糖、总胆固醇、甘油三酯、高密度脂蛋白、尿酸、谷丙转氨酶显著高于无NAFLD组(p<0.05)。②NAFLD组合并肥胖、高血压、脂代谢异常、高血糖和代谢综合征显著高于无脂肪肝组(p<0.05)。③NAFLD组按体重指数进行分层,随体重指数的升高,腹型肥胖、高血压、高甘油三脂血症、低密度脂蛋白血症、空腹血糖受损等患病率显著升高(p<0.05);相同体重指数水平下,上述各病患病率之间没有显著差异。结论NAFLD患者存在明显的代谢综合征各组分集聚的特征。临床上应对NAFLD患者及时筛查代谢综合征及其组成疾病的患病情况,使诊治科学合理。     

Long-Term Androgen-Induced Nonalcoholic Fatty Liver Disease in a Polycystic Ovary Syndrome Mouse Model is Related to Mitochondrial Dysfunction

Objective::Metabolic disorders are markedly common in women with polycystic ovary syndrome (PCOS), and nonalcoholic fatty liver disease (NAFLD) is observed in 3...     

The Influence of Dietary Fat on Liver Fat Accumulation

Obesity is a known risk factor for the development of non-alcoholic fatty liver disease (NAFLD); however, it has been suggested that dietary fat, both amount and composition, may play a pivotal role in its development, independent of body fatness. Studies that have investigated the role of dietary fat on liver fat accumulation are reasonably sparse. We review here the available work that has investigated the impact of dietary fat: amount, composition and frequency, on liver fat accumulation in human observational and intervention studies. Overall, it would seem that total calorie consumption, rather than dietary fat composition, is an important factor in the development of fatty liver disease in humans.     

Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018

The European Journal of Health Economics - Non-alcoholic steatohepatitis (NASH) – a progressive subset of non-alcoholic fatty liver disease (NAFLD) – is a chronic liver disease that can...     

The Other Side of Malnutrition in Inflammatory Bowel Disease (IBD): Non-Alcoholic Fatty Liver Disease

Steatohepatitis and hepatobiliary manifestations constitute some of the most common extra-intestinal manifestations of Inflammatory Bowel Disease (IBD). On the other hand, non-alcoholic fatty liver disease (NAFLD) affects around 25% of the world’s population and is attracting ever more attention in liver transplant programs. To outline the specific pathways linking these two conditions is a pressing task for 21st-century researchers. We are accustomed to expecting the occurrence of fatty liver disease in obese people, but current evidence suggests that there are several different pathways also occurring in underweight patients. Genetic factors, inflammatory signals and microbiota are key players that could help in understanding the entire pathogenesis of NAFLD, with the aim of defining the multiple expressions of malnutrition. In the current review, we summarize the most recent literature regarding the epidemiology, pathogenesis and future directions for the management of NAFLD in patients affected by IBD.     

Mediterranean Diet: A Tool to Break the Relationship of Atrial Fibrillation with the Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease

Atrial fibrillation (AF) is the most common supraventricular arrhythmia associated with increased cardiovascular and non-cardiovascular morbidity and mortality. As multiple factors may predispose the onset of AF, the prevention of the occurrence, recurrence and complications of this arrhythmia is still challenging. In particular, a high prevalence of cardio-metabolic comorbidities such as the metabolic syndrome (MetS) and in its hepatic manifestation, the non-alcoholic fatty liver disease (NAFLD), have been described in the AF population. A common pathogenetic mechanism linking AF, MetS and NAFLD is represented by oxidative stress. For this reason, in the past decades, numerous studies have investigated the effect of different foods/nutrients with antioxidant properties for the prevention of, and their therapeutic role is still unclear. In this narrative comprehensive review, we will summarize current evidence on (1) the association between AF, MetS and NAFLD (2) the antioxidant role of Mediterranean Diet and its components for the prevention of AF and (3) the effects of Mediterranean Diet on MetS components and NAFLD.